/ 2 items

#RNA↓

Featured/ RNA/ 10/27/2025 · 6:53 AM

Novartis Makes Bold $12 Billion Move with Avidity Biosciences Acquisition in Largest Deal Under CEO Narasimhan

Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.

Featured/ RNA/ 08/06/2025 · 12:03 PM

Novartis Pursues Avidity: A Bid for Rare Disease Dominance

Novartis targets rare disease biotech Avidity Biosciences in a $4.3B takeover bid, aiming to boost its pipeline and offset major patent cliffs.